Navitas Life Sciences

Navitas Life Sciences is a technology-led contract research organisation (CRO) headquartered in Princeton, New Jersey, with 1,000+ employees across five countries. It provides end-to-end product development and regulatory compliance solutions for pharmaceutical, biotech and medical device companies, combining regulatory technology platforms with consulting services to help them navigate global regulatory requirements.

Its flagship product is the pharmaREADY Suite, an integrated, regulatory-compliant platform launched in 2005 comprising Document Management (DMS), Electronic Common Technical Document (eCTD), Structured Product Labeling (SPL) and Training Records Management System (TRMS) modules. The suite serves 200+ global biopharma customers. The vendor states 100% customer satisfaction and relationships spanning 10+ years with named pharmaceutical companies.

Navitas also provides CRO services beyond regulatory technology: regulatory compliance management, pharmacovigilance and patient safety, bioanalytical services, and clinical trial support. The company is owned by H.I.G. Capital, a private equity firm.

Navitas Life Sciences is exclusively focused on the pharmaceutical, biotechnology and medical device industries, with purpose-built regulatory technology and CRO services. The pharmaREADY platform is designed for FDA 21 CFR Part 11, EU Annex 11, cGMP and HIPAA compliance requirements.

200+ global biopharma customers are served, including named customers Hikma Pharmaceuticals, Reliance Life Sciences (1,000+ users over 10+ years) and BioVectra. Market penetration spans generic drug manufacturers, innovator pharmaceutical companies, biotechnology firms and contract development and manufacturing organisations (CDMOs).

Zero observations were recorded in the company's last three FDA inspections. Navitas holds ISO 27001:2022, ISO 9001:2015 and ISO 15189 certifications, plus CAP accreditation. GAMP5, GxP and 21 CFR Part 11 standards are applied across all services.

Navitas Life Sciences is privately held and owned by H.I.G. Capital, a global alternative investment firm with $66 billion of capital under management, which acquired Navitas as part of its healthcare and life sciences portfolio. Revenue, profitability and funding-round figures are undisclosed.

pharmaREADY's customer count grew from 100 in 2016 to 200+ in 2021. The employee base has grown to 1,000+ across five countries. The pharmaREADY Suite has received ongoing enhancements, including expansion into AI-powered compliance features.

Navitas sells the pharmaREADY Suite, launched in 2005 and used by 200+ customers, alongside a set of CRO services. The suite comprises four modules: DMS (Document Management System) for centralised regulatory document control with 21 CFR Part 11 compliance, electronic signatures and automated workflows; eCTD (Electronic Common Technical Document) for regulatory submission preparation and publishing to global health authorities; SPL (Structured Product Labeling) for automated creation and management of FDA-compliant product labelling; and TRMS (Training Records Management System) for GxP-compliant training administration and tracking. The vendor states the suite enables 40% faster submission preparation through integration across modules. Implementation runs 3–4 weeks, including IQ/OQ validation, with cloud and on-premise deployment options and 24/7 global support.

CRO services offered alongside the suite: regulatory compliance management and strategy, pharmacovigilance and patient safety services, bioanalytical laboratory services (CAP accredited, ISO 15189 certified), clinical trial support and management, quality assurance and regulatory consulting, and medical writing and regulatory submission support.

CAP (College of American Pathologists) accreditation covers Navitas's laboratory services. As part of H.I.G. Capital's portfolio, Navitas has access to a network of other healthcare and life sciences companies for collaboration and knowledge sharing. Technology partnerships integrate the pharmaREADY platform with existing pharmaceutical IT infrastructure. Specific technology alliances are undisclosed.

Navitas operates as both a software vendor and a services partner, a hybrid model that lets customers adopt the pharmaREADY platform while also drawing on Navitas's regulatory expertise for implementation, validation and ongoing compliance support.

Implementation runs 3–4 weeks, covering configuration, IQ/OQ validation and end-user training. Additional implementation services include data migration from legacy document management systems, workflow configuration tailored to organisational processes, integration support across pharmaREADY suite modules, and validation documentation aligned with FDA 21 CFR Part 11 and GAMP5.

Ongoing support is available 24/7 from technical personnel, with platform updates designed for minimal re-validation, proactive monitoring and issue resolution, and regulatory compliance updates tracking FDA, EMA and ICH requirements.

Professional services cover regulatory consulting and compliance strategy, validation consulting for computerised systems, regulatory submission support and preparation, training programmes for regulatory affairs professionals, and quality system assessments and remediation.

Hikma Pharmaceuticals is quoted: "fast response and solutions which is critical when working with authorities" (Hikma Pharmaceuticals).

Navitas holds ISO 27001:2022 (certified 11 January 2025), ISO 9001:2015 (certified 31 January 2025) and ISO 15189 (Medical Laboratories Quality and Competence) certifications, plus CAP (College of American Pathologists) accreditation for laboratory services.

Zero observations were recorded in the company's last three FDA inspections. pharmaREADY has operated for 15+ years since its 2005 launch, with sustained customer growth. GAMP5, GxP and 21 CFR Part 11 standards are applied across all services. The vendor states 200+ pharmaceutical customers and 100% customer satisfaction.

Reliance Life Sciences has been a customer for 10+ years, with 1,000+ users across departments. Hikma Pharmaceuticals has been a customer for 10+ years and is quoted: "very pleased with user-friendly software" (Hikma Pharmaceuticals). The customer base grew from 100 in 2016 to 200+ in 2021.

Navitas is backed by H.I.G. Capital, a $66 billion global private equity firm specialising in healthcare investments.

Navitas maintains a corporate website (navitaslifesciences.com) and a product website (pharmaready.com), both actively updated, alongside a LinkedIn company page and a technical blog covering regulatory compliance and product updates.

Operations span 1,000+ employees across five countries in North America, Europe and Asia, headquartered in Princeton, New Jersey, a pharmaceutical industry hub. The multi-country presence supports local coverage for international pharmaceutical customers.

Customer communication includes annual pharmaREADY User Group meetings, webinars and training programmes, and published case studies and testimonials for Hikma, Reliance, BioVectra and other customers. Educational content covers FDA 21 CFR Part 11, EU Annex 11 and GAMP5 compliance.

The customer base grew from 100 in 2016 to 200+ in 2021. Analyst coverage and third-party review presence are limited.